Top Back to top

Cellular Therapy & Immunobiology Working Party: Call for participation DLI Study


We would like to invite you to participate in a retrospective study of the EBMT Cellular Therapy and Immunobiology Working Party regarding: Donor Lymphocyte Infusions (DLI) after haploidentical stem cell transplantation.

In this retrospective study, the outcomes of patients receiving DLI after T-cell replete haplo-SCT with post-transplantation cyclophosphamide will be evaluated, focusing either for prophylactic or for preemptive use.

The inclusion criteria are:

  • Adults (18 years)
  • Hematological malignancies
  • Received DLI post T-cell replete haplo-SCT with Pt-Cy approach
  • First DLI in EBMT transplant centres between January 2008 and December 2018

The exclusion criteria are:

  • Prior allogeneic HSCT (autologous HSCT permitted)
  • Disease of secondary origin or transformed

If you are interested in this study, please contact the study coordinator: Jorinde Hoogenboom ( and we can send you the study questionnaire and work instructions.

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to